Highlights

  • AVITA Medical (ASX:AVH) reported September-quarter Revenue of USD 26.1 million.
  • Third-quarter revenue increased 53% year on year and 20% sequentially.
  • Full-year 2026 revenue guidance increased to USD 92–94 million.
  • Quarter-end cash and marketable securities totalled approximately USD 10.5 million.

AVITA Medical Inc develops and markets products for acute wound care, including the RECELL skin-cell treatment system and complementary wound-management products. On 16 November 2026, AVITA Medical (ASX:AVH) was trading at AUD 4.61, down 2.74% during the session. The company’s November financial release reported higher September-quarter product revenue, an updated full-year sales range and changes in cash use, while several clinical and reimbursement developments remain relevant to future operations.

Commercial Products and Markets

AVITA (ASX:AVH), also listed on Nasdaq under RCEL, operates principally in acute wound care. RECELL supports the preparation and delivery of autologous skin cells, while Cohealyx and PermeaDerm form parts of the company’s commercial portfolio. The group sells to clinical providers and reports United States product revenue alongside international contributions. Adoption can depend on clinician training, hospital procurement decisions and product reimbursement.

RECELL remained the largest reported third-quarter product contributor. The Business also continued selling Cohealyx and PermeaDerm, giving it multiple products within the same clinical area. Product-specific revenue trends should be considered separately because adoption patterns and purchasing decisions vary between medical facilities.

September-Quarter Revenue and Guidance

AVITA (ASX:AVH) reported third-quarter 2026 revenue of USD 26.1 million, up 53% from USD 17.1 million in the corresponding 2025 quarter and 20% from the preceding quarter. United States RECELL revenue totalled USD 22.4 million, approximately 20% higher sequentially. Cohealyx generated USD 2.1 million, an increase of approximately 21% from the second quarter. PermeaDerm revenue was USD 0.6 million, while international revenue was USD 0.9 million.

Gross Margin reached 84.0%, rising 270 basis points from the comparable prior-year quarter. Operating expenses totalled USD 24.6 million, broadly unchanged sequentially. Net loss narrowed to USD 6.2 million from USD 13.2 million a year earlier. These figures indicate changes in operating scale and reported profitability, although the company still recorded a quarterly loss.

Liquidity, Regulatory and Clinical Updates

Net cash use was approximately USD 0.6 million during the September quarter, against USD 3.2 million in the June quarter. Cash, cash equivalents and marketable securities totalled about USD 10.5 million at 30 September 2026. Following quarter-end, the company drew a further USD 10 million under an existing Credit Facility after meeting a trailing twelve-month revenue milestone of USD 85 million, taking total borrowings under that facility to USD 60 million.

AVITA (ASX:AVH) lifted its FY26 revenue guidance to USD 92–94 million from USD 86–89 million and reaffirmed its expectation of reaching cash-flow breakeven in the fourth quarter. Guidance is a management expectation rather than a completed result. The company also disclosed finalised United States Medicare physician-payment values and simplified RECELL billing codes scheduled to take effect on 1 January 2027.

Results from a PermeaDerm clinical study reported comparable outcomes to allograft on the assessed measures, alongside company-reported reductions of 70% in product costs and 95.7% in preparation time. These findings relate to the study conditions and should not be read as guarantees across all clinical settings.

Risks to Consider

Hospital adoption, reimbursement policy, supply-chain execution and clinical evidence can affect revenue. AVITA must manage operating costs and Debt obligations while pursuing its cash-flow objective. Changes in product mix or procurement cycles could affect gross margin. The additional borrowing improves immediate Liquidity but also creates financing commitments that require continued cash generation.

What to Watch Next

Items for monitoring include fourth-quarter sales against the revised FY26 guidance, achievement or otherwise of the stated cash-flow objective, RECELL procedure volumes and early effects of the 2027 Medicare coding changes. Continued reporting on Cohealyx and PermeaDerm uptake will provide information on sales mix.

Key Insights

AVITA (ASX:AVH) reported higher revenue, narrower losses and reduced quarterly cash use for September 2026. Revised guidance reflects management’s current sales expectations, while reimbursement changes and borrowings remain relevant. Subsequent cash-flow and product-revenue disclosures will be central to evaluating execution.